Research Analysts’ Weekly Ratings Changes for Natera (NTRA)

Several brokerages have updated their recommendations and price targets on shares of Natera (NASDAQ: NTRA) in the last few weeks:

• 11/18/2024 – Natera had its price target raised by analysts at Piper Sandler from $150.00 to $200.00. They now have an “overweight” rating on the stock.
• 11/14/2024 – Natera was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 11/14/2024 – Natera had its price target raised by analysts at Morgan Stanley from $132.00 to $176.00. They now have an “overweight” rating on the stock.
• 11/13/2024 – Natera had its price target raised by analysts at JPMorgan Chase & Co. from $135.00 to $160.00. They now have an “overweight” rating on the stock.
• 11/13/2024 – Natera had its price target raised by analysts at Robert W. Baird from $120.00 to $160.00. They now have an “outperform” rating on the stock.
• 11/13/2024 – Natera had its price target raised by analysts at TD Cowen from $155.00 to $175.00. They now have a “buy” rating on the stock.
• 11/13/2024 – Natera had its price target raised by analysts at Craig Hallum from $121.00 to $157.00. They now have a “buy” rating on the stock.
• 11/13/2024 – Natera had its price target raised by analysts at Canaccord Genuity Group Inc. from $150.00 to $165.00. They now have a “buy” rating on the stock.
• 11/6/2024 – Natera was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 10/30/2024 – Natera had its price target raised by analysts at Sanford C. Bernstein from $125.00 to $135.00. They now have an “outperform” rating on the stock.
• 10/29/2024 – Natera had its price target raised by analysts at Canaccord Genuity Group Inc. from $145.00 to $150.00. They now have a “buy” rating on the stock.
• 10/25/2024 – Natera was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 10/17/2024 – Natera had its price target raised by analysts at Leerink Partners from $140.00 to $150.00. They now have an “outperform” rating on the stock.
• 10/17/2024 – Natera was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 10/16/2024 – Natera had its price target raised by analysts at The Goldman Sachs Group, Inc. from $125.00 to $140.00. They now have a “buy” rating on the stock.

Natera Price Performance

Natera stock traded down $0.10 during midday trading on Wednesday, reaching $168.22. The company’s stock had a trading volume of 365,694 shares, compared to its average volume of 1,344,801. The firm has a market capitalization of $22.21 billion, a PE ratio of -95.58 and a beta of 1.53. Natera, Inc. has a fifty-two week low of $53.88 and a fifty-two week high of $171.95. The stock’s 50 day simple moving average is $133.05 and its 200 day simple moving average is $119.08. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm had revenue of $439.80 million during the quarter, compared to analysts’ expectations of $361.43 million. During the same period in the previous year, the firm posted ($0.95) earnings per share. Natera’s revenue was up 63.9% on a year-over-year basis. On average, equities research analysts forecast that Natera, Inc. will post -1.66 earnings per share for the current year.

Insider Transactions at Natera

In other news, insider Solomon Moshkevich sold 256 shares of Natera stock in a transaction that occurred on Tuesday, October 22nd. The shares were sold at an average price of $120.07, for a total transaction of $30,737.92. Following the sale, the insider now owns 111,891 shares in the company, valued at $13,434,752.37. This trade represents a 0.23 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Steven Leonard Chapman sold 5,024 shares of the business’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $128.48, for a total transaction of $645,483.52. Following the completion of the transaction, the chief executive officer now owns 195,686 shares in the company, valued at $25,141,737.28. This represents a 2.50 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 46,503 shares of company stock worth $6,325,804 in the last three months. Company insiders own 7.60% of the company’s stock.

Hedge Funds Weigh In On Natera

Hedge funds have recently added to or reduced their stakes in the business. Farallon Capital Management LLC boosted its stake in Natera by 13.6% in the second quarter. Farallon Capital Management LLC now owns 4,460,557 shares of the medical research company’s stock valued at $483,034,000 after acquiring an additional 532,874 shares during the period. Wellington Management Group LLP lifted its stake in Natera by 205.4% in the third quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company’s stock valued at $355,493,000 after buying an additional 1,883,481 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its position in Natera by 3.6% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 2,482,818 shares of the medical research company’s stock valued at $315,194,000 after purchasing an additional 85,236 shares during the last quarter. Geode Capital Management LLC boosted its stake in Natera by 7.4% during the 3rd quarter. Geode Capital Management LLC now owns 2,090,480 shares of the medical research company’s stock valued at $265,747,000 after purchasing an additional 143,825 shares during the period. Finally, Duquesne Family Office LLC raised its holdings in shares of Natera by 2.4% during the second quarter. Duquesne Family Office LLC now owns 1,974,880 shares of the medical research company’s stock valued at $213,860,000 after buying an additional 45,500 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.